: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription

Articles published in Clin Gastroenterol Hepatol
Retrieve available abstracts of 391 articles:
HTML format

Single Articles

August 2024

WEWER MD, Letnar G, Andersen KK, Malham M, et al
Thiopurines and the Risk of Cancer in Patients with Inflammatory Bowel Disease and Reference Individuals without Inflammatory Bowel Disease - A Danish Nationwide Cohort Study (1996-2018).
Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00772.
PubMed Abstract available

GOODSALL TM, An YK, Andrews JM, Begun J, et al
Reliability of intestinal ultrasound for evaluating Crohn's disease activity using point-of-care and central reading.
Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00773.
PubMed Abstract available

REVES J, Fernandez-Clotet A, Ordas I, Buisson A, et al
Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn's disease.
Clin Gastroenterol Hepatol. 2024 Aug 27:S1542-3565(24)00769.
PubMed Abstract available

SHEHAB M, Alrashed F, Alsayegh A, Aldallal U, et al
Comparative Efficacy of Biologics and Small Molecule in Ulcerative Colitis: A Systematic Review and Network Meta-analysis.
Clin Gastroenterol Hepatol. 2024 Aug 23:S1542-3565(24)00767.
PubMed Abstract available

IOANNOU S, Beecham A, Gomez L, Dauer R, et al
Ancestral diversity in pharmacogenomics affects treatment for Hispanic/Latine populations with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2024 Aug 22:S1542-3565(24)00766.
PubMed Abstract available

MCLAUGHLIN JF, Linville T, Jester TW, Marciano TA, et al
Travel Time to Treating Center is Associated with Diagnostic Delay in Pediatric Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2024 Aug 22:S1542-3565(24)00761.
PubMed Abstract available

HANNA LN, Anandabaskaran S, Iqbal N, Geldof J, et al
Perianal fistulising Crohn's disease: utilising the TOpClass classification in clinical practice to provide targeted individualised care.
Clin Gastroenterol Hepatol. 2024 Aug 10:S1542-3565(24)00692.
PubMed Abstract available

KAHN-BOESEL O, Araka E, Anyane-Yeboa A, Ufere NN, et al
The Discrepant Visual Representation of Inflammatory Bowel Diseases in the Internet and Media.
Clin Gastroenterol Hepatol. 2024;22:1555-1560.
PubMed

BARNES EL, Karachalia Sandri A, Herfarth HH, Jess T, et al
Antibiotic Use in the 12 Months Prior to Ileal Pouch-Anal Anastomosis Increases the Risk for Pouchitis.
Clin Gastroenterol Hepatol. 2024;22:1678-1686.
PubMed Abstract available

July 2024

MAGRO F, Peyrin-Biroulet L, Sands BE, Danese S, et al
Endoscopic, Histologic, and Composite Endpoints in Patients with Ulcerative Colitis Treated with Etrasimod [106/120 characters, including spaces].
Clin Gastroenterol Hepatol. 2024 Jul 30:S1542-3565(24)00681.
PubMed Abstract available

ERNEST-SUAREZ K, Murguia-Favela LE, Constantinescu C, Fitzpatrick T, et al
LIVE ROTAVIRUS VACCINATION APPEARS LOW-RISK IN INFANTS BORN TO MOTHERS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS.
Clin Gastroenterol Hepatol. 2024 Jul 30:S1542-3565(24)00677.
PubMed Abstract available

OHARA J, Maeda Y, Ogata N, Kuroki T, et al
Automated Neutrophil Quantification and Histological Score Estimation in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2024 Jul 24:S1542-3565(24)00668.
PubMed Abstract available

MA C, Solitano V, Danese S, Jairath V, et al
THE FUTURE OF CLINICAL TRIALS IN INFLAMMATORY BOWEL DISEASE.
Clin Gastroenterol Hepatol. 2024 Jul 16:S1542-3565(24)00635.
PubMed Abstract available

CHAVANNES M, Dolinger MT, Cohen-Mekelburg S, Abraham B, et al
AGA Clinical Practice Update on the Role of Intestinal Ultrasound in Inflammatory Bowel Disease: Commentary.
Clin Gastroenterol Hepatol. 2024 Jul 10:S1542-3565(24)00454.
PubMed Abstract available

LOPES EW, Turpin W, Croitoru K, Colombel JF, et al
Prediction and Prevention of Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2024 Jul 10:S1542-3565(24)00597.
PubMed

SILVERMAN AL, Shung D, Stidham RW, Kochhar GS, et al
How Artificial Intelligence Will Transform Clinical Care, Research, and Trials for Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2024 Jul 9:S1542-3565(24)00598.
PubMed Abstract available

GAO L, Fang K, Dong X, Bai J, et al
Additional yield of random biopsy in patients with inflammatory bowel disease: A systematic review and meta-analysis.
Clin Gastroenterol Hepatol. 2024 Jul 5:S1542-3565(24)00556.
PubMed Abstract available

INNOCENTI T, Rocco C, Lynch EN, Milla M, et al
Applicability of the International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) to ulcerative colitis: a preliminary study.
Clin Gastroenterol Hepatol. 2024 Jul 4:S1542-3565(24)00607.
PubMed

ROCHA CH, Turpin W, Borowski K, Stempak JM, et al
After surgically induced remission, ileal and colonic mucosa-associated microbiota predicts Crohn's disease recurrence.
Clin Gastroenterol Hepatol. 2024 Jul 3:S1542-3565(24)00592.
PubMed Abstract available

ATREYA R, Neurath MF
Biomarkers for Personalizing IBD Therapy: The Quest Continues.
Clin Gastroenterol Hepatol. 2024;22:1353-1364.
PubMed Abstract available

KHAKOO NS, Beecham AH, Lyu J, Quintero MA, et al
Early Life and Childhood Environmental Exposures, More Than Genetic Predisposition, Influence Age of Diagnosis in a Diverse Cohort of 2952 Patients With IBD.
Clin Gastroenterol Hepatol. 2024;22:1462-1474.
PubMed Abstract available

TORRES J, Hanauer SB
EXPLORing the Therapeutic Ceiling in Crohn's Disease: Will Combination Pave the Way?
Clin Gastroenterol Hepatol. 2024;22:1377-1378.
PubMed

June 2024

BUISSON A, Junda J, Vignette J, Lecoq E, et al
Development and validation of a score to assess transmural healing and response in patients with Crohn's disease.
Clin Gastroenterol Hepatol. 2024 Jun 20:S1542-3565(24)00546.
PubMed Abstract available

TORRES J, Mahadevan U
Editorial: Ustekinumab and Vedolizumab Safety and Clearance in Pregnancy with Inflammatory Bowel Disease: Stop the Disease, not the Drug!
Clin Gastroenterol Hepatol. 2024 Jun 13:S1542-3565(24)00543.
PubMed

WONG SY, Rowan C, Brockmans ED, Law CC, et al
Perianal fistulizing Crohn's disease-associated anorectal and fistula cancers: systematic review and expert consensus.
Clin Gastroenterol Hepatol. 2024 Jun 11:S1542-3565(24)00504.
PubMed Abstract available

May 2024

CAENEPEEL C, Deleu S, Vazquez Castellanos JF, Arnauts K, et al
RIGOROUS DONOR SELECTION FOR FMT IN ACTIVE ULCERATIVE COLITIS: KEY LESSONS FROM A RANDOMIZED CONTROLLED TRIAL HALTED FOR FUTILITY.
Clin Gastroenterol Hepatol. 2024 May 22:S1542-3565(24)00492.
PubMed Abstract available

GARGALLO-PUYUELO CJ, Ricart E, Iglesias E, de Francisco R, et al
SEX-RELATED DIFFERENCES IN THE PHENOTYPE AND COURSE OF INFLAMMATORY BOWEL DISEASE: SEXEII STUDY OF ENEIDA.
Clin Gastroenterol Hepatol. 2024 May 21:S1542-3565(24)00487.
PubMed Abstract available

YANG Y, Ludvigsson JF, Forss A, Faucon AL, et al
Risk of kidney failure in patients with inflammatory bowel disease undergoing colectomy: a nationwide cohort study.
Clin Gastroenterol Hepatol. 2024 May 20:S1542-3565(24)00484.
PubMed Abstract available

ITZKOWITZ SH, Jiang Y, Villagra C, Colombel JF, et al
Safety of Immunosuppression in A Prospective Cohort of Inflammatory Bowel Disease Patients with a HIstoRy of CancEr: SAPPHIRE Registry.
Clin Gastroenterol Hepatol. 2024 May 18:S1542-3565(24)00479.
PubMed Abstract available

DAI C, Huang YH, Jiang M
Antibiotic Use and the Risk of Pouchitis after Ileal Pouch-Anal Anastomosis for Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2024 May 17:S1542-3565(24)00491.
PubMed

XUE M, Leibovitzh H, Jingcheng S, Neustaeter A, et al
Environmental Factors Associated with Risk of Crohn's Disease Development in the CCC-GEM Project.
Clin Gastroenterol Hepatol. 2024 May 15:S1542-3565(24)00450.
PubMed Abstract available

AXELRAD JE, Hashash JG, Itzkowitz SH
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Patients with Malignancy: Commentary.
Clin Gastroenterol Hepatol. 2024 May 14:S1542-3565(24)00354.
PubMed Abstract available

PUDIPEDDI A, Paramsothy S, Kariyawasam V, Paramsothy R, et al
Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial.
Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00426.
PubMed Abstract available

MOULTON CD, Young AH, Hart AL
Targeting durable remission of fatigue in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00433.
PubMed

AGRAWAL M, Stordal K, Hansen AV, Ostensson M, et al
Breastfeeding duration is not associated with offspring inflammatory bowel disease risk in three population-based birth cohorts.
Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00416.
PubMed Abstract available

FUMERY M, Caron B, Hebuterne X, Altwegg R, et al
Long-term outcome of risankizumab in Crohn's disease: a real-world GETAID study.
Clin Gastroenterol Hepatol. 2024 May 8:S1542-3565(24)00423.
PubMed Abstract available

SANDS BE, D'Haens G, Panaccione R, Regueiro M, et al
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00405.
PubMed Abstract available

ALI S, Pasternak B, Moses J, Suskind DL, et al
Characterization of Biologic Discontinuation Among Pediatric Patients with Crohn's Disease.
Clin Gastroenterol Hepatol. 2024 May 7:S1542-3565(24)00406.
PubMed Abstract available

ROBLIN X, Moschetti E, Barrau M, Cheifetz AS, et al
Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn's disease.
Clin Gastroenterol Hepatol. 2024 May 3:S1542-3565(24)00402.
PubMed

SOFIA MA, Feuerstein JD, Narramore L, Chachu KA, et al
White Paper: American Gastroenterological Association Position Statement: The Future of IBD Care in the United States-Removing Barriers and Embracing Opportunities.
Clin Gastroenterol Hepatol. 2024;22:944-955.
PubMed Abstract available

SINGH S, Velayos FS, Rubin DT
Common Instances of Low-value Care in Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2024;22:923-932.
PubMed Abstract available

MAHMUD O, Fatimi AS, Mahar MU, Jahangir A, et al
Sphingosine 1-Phosphate Receptor Modulators are Effective in Patients With Moderately to Severely Active Ulcerative Colitis and a Prior Biologic Exposure: A Meta-Analysis of Randomized Controlled Trials.
Clin Gastroenterol Hepatol. 2024;22:1139-1141.
PubMed

April 2024

PAPAMICHAEL K, Centritto A, Guillo L, Hier J, et al
Higher adalimumab concentration is associated with complete fistula healing in patients with perianal fistulizing Crohn's disease.
Clin Gastroenterol Hepatol. 2024 Apr 29:S1542-3565(24)00397.
PubMed

March 2024

BAGER P, Hvas CL, Dahlerup JF
Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy with Modanfinil or Vitamin Therapy with Thiamine.
Clin Gastroenterol Hepatol. 2024 Mar 18:S1542-3565(24)00283.
PubMed

PRENTICE R, Flanagan E, Wright EK, Gibson PR, et al
Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero.
Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00252.
PubMed Abstract available

PEYRIN-BIROULET L, Panaccione R, Louis E, Atreya R, et al
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00253.
PubMed Abstract available

COLOMBEL JF, Hisamatsu T, Atreya R, Bresso F, et al
Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy.
Clin Gastroenterol Hepatol. 2024 Mar 14:S1542-3565(24)00254.
PubMed Abstract available

GUPTA A, Peyrin-Biroulet L, Ananthakrishnan AN
Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2024;22:499-512.
PubMed Abstract available

BOYD T, Ananthakrishnan AN
Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States.
Clin Gastroenterol Hepatol. 2024;22:659-661.
PubMed Abstract available

February 2024

AXELRAD JE, Rubin DT
The Management of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00108.
PubMed

WIJNANDS AM, Penning de Vries BBL, Lutgens MWMD, Bakhshi Z, et al
Dynamic prediction of advanced colorectal neoplasia in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2024 Feb 29:S1542-3565(24)00214.
PubMed Abstract available

NARULA N, Wong ECL, Dulai PS, Patel J, et al
Defining Endoscopic Remission in Crohn's Disease: MM-SES-CD and SES-CD Thresholds Associated with Low Risk of Disease Progression.
Clin Gastroenterol Hepatol. 2024 Feb 28:S1542-3565(24)00212.
PubMed Abstract available

DUAN R, Zhang C, Li G, Li J, et al
Antibiotic exposure and risk of new-onset inflammatory bowel disease: a systematic review and dose-response meta-analysis.
Clin Gastroenterol Hepatol. 2024 Feb 27:S1542-3565(24)00218.
PubMed Abstract available

BRENNER EJ, Weaver KN, Zhang X, Kastl AJ, et al
Long-Term Effectiveness and Durability of COVID-19 Vaccination among Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2024 Feb 16:S1542-3565(24)00203.
PubMed Abstract available

POLYDORIDES AD
Assessment and significance of histologic activity in Crohn disease.
Clin Gastroenterol Hepatol. 2024 Feb 14:S1542-3565(24)00196.
PubMed

KOCHAR B, Ananthakrishnan AN, Ritchie CS
Pharmacoequity for Older Adults With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2024;22:209-214.
PubMed

CONSTANT BD, Albenberg L, Mitchel EB, De Zoeten EF, et al
Prior Authorizations Delay Therapy, Impact Decision-making, and Lead to Adverse Events in Inflammatory Bowel Disease: 2022 Provider Survey.
Clin Gastroenterol Hepatol. 2024;22:423-426.
PubMed

LAPP SL, Bewtra M, Lewis JD
Yield of Serial Testing for Tuberculosis Exposure in Patients With Inflammatory Bowel Diseases: One Test is Not Enough.
Clin Gastroenterol Hepatol. 2024;22:420-422.
PubMed

CORSETTI M, Ballou S
Symptom Subgroups Taking Into Account Psychological Burden Predicts Irritable Bowel Syndrome Disease Impact and Burden: A Step Forward?
Clin Gastroenterol Hepatol. 2024;22:237-240.
PubMed

TE GROEN M, Derks M, den Broeder N, Peters C, et al
Quality of Surveillance Impacts the Colitis-Associated Advanced Neoplasia Risk: A Multicenter Case-Control Study.
Clin Gastroenterol Hepatol. 2024;22:357-367.
PubMed Abstract available

January 2024

KEDIA S, Virmani S, Bajaj A, Markandey M, et al
Coconut water induces clinical remission in mild to moderate ulcerative colitis: double-blind placebo controlled trial.
Clin Gastroenterol Hepatol. 2024 Jan 24:S1542-3565(24)00088.
PubMed Abstract available

AHUJA D, Luo J, Qi Y, Syal G, et al
Impact of Treatment Response on Risk of Serious Infections in Patients with Crohn's Disease: Secondary Analysis of the PYRAMID Registry.
Clin Gastroenterol Hepatol. 2024 Jan 10:S1542-3565(24)00047.
PubMed Abstract available

MEYER A, Miranda S, Drouin J, Weill A, et al
Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2024 Jan 8:S1542-3565(24)00010.
PubMed Abstract available

MOULTON CD, Young AH, Hart AL
Modafinil for severe fatigue in inflammatory bowel disease: a prospective case series.
Clin Gastroenterol Hepatol. 2024 Jan 6:S1542-3565(24)00011.
PubMed

VUYYURU SK, Nguyen TM, Murad MH, Narula N, et al
Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Clin Gastroenterol Hepatol. 2024 Jan 5:S1542-3565(24)00003.
PubMed Abstract available

KATIBIAN DJ, Solitano V, Polk DB, Nguyen T, et al
Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2024;22:22-33.
PubMed Abstract available

LEMMENS P, Louis E, Van Moerkercke W, Pouillon L, et al
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
Clin Gastroenterol Hepatol. 2024;22:154-163.
PubMed Abstract available

DE MELLO MK, Freitas Queiroz NS, Papamichael K
Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?
Clin Gastroenterol Hepatol. 2024;22:200-201.
PubMed

December 2023

AGRAWAL M, Midya V, Maroli A, Magee J, et al
Per- and poly-fluoroalkyl substances (PFAS) exposure is associated with later occurrence of inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2023 Dec 26:S1542-3565(23)01055.
PubMed

NIGAM GB, Limdi JK, Bate S, Hamdy S, et al
Fecal Urgency in Ulcerative Colitis: Impact on Quality of Life and Psychological Well-being in Active and Inactive Disease States.
Clin Gastroenterol Hepatol. 2023 Dec 25:S1542-3565(23)01054.
PubMed

ELMASRY S, Ha C
Evidence-Based Approach to the Management of Mild Crohn's Disease.
Clin Gastroenterol Hepatol. 2023 Dec 20:S1542-3565(23)00949.
PubMed

MCCURDY J, Munir J, Parlow S, Reid J, et al
Development of an MRI-based prediction model for anti-TNF treatment failure in perianal Crohn's disease: A multicenter study.
Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01035.
PubMed Abstract available

MURTHY SK, Bernstein CN, Nguyen GC, Jairath V, et al
Interim Analysis of a Trial Evaluating the Utility of Non-Targeted Biopsies for Colorectal Neoplasia Detection in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2023 Dec 18:S1542-3565(23)01036.
PubMed

SINGH S, Allegretti J, Nersesova Y, Serra S, et al
Meeting Summary: AGA Roundtable on Clinical Trial Design in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2023 Dec 16:S1542-3565(23)01033.
PubMed

ZINGER A, Choi D, Choi N, Cohen RD, et al
Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data from a Large Tertiary Center.
Clin Gastroenterol Hepatol. 2023 Dec 6:S1542-3565(23)00998.
PubMed

SOLITANO V, Schaeffer DF, Hogan M, Casteele NV, et al
Reliability and Responsiveness of Histologic Indices for the Assessment of Crohn's Disease Activity.
Clin Gastroenterol Hepatol. 2023 Dec 4:S1542-3565(23)00969.
PubMed Abstract available

SCHREGEL I, Ramos GP, Ioannou S, Culver E, et al
Evaluation of Tofacitinib in Primary Sclerosing Cholangitis and Associated Colitis: A Multicenter, Retrospective Study.
Clin Gastroenterol Hepatol. 2023;21:3448-3450.
PubMed

November 2023

ARMUZZI A, Cross RK, Lichtenstein GR, Hou J, et al
Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses.
Clin Gastroenterol Hepatol. 2023 Nov 29:S1542-3565(23)00956.
PubMed Abstract available

KAWADA T
Fecal calprotectin profiles in Crohn's disease: a longitudinal data analysis.
Clin Gastroenterol Hepatol. 2023 Nov 28:S1542-3565(23)00953.
PubMed

MAGRO F, Protic M, De Hertogh G, Chan LS, et al
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial.
Clin Gastroenterol Hepatol. 2023 Nov 20:S1542-3565(23)00948.
PubMed Abstract available

JAIRATH V, Yarur A, Osterman MT, James A, et al
ENTERPRET: a randomized controlled trial of vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse.
Clin Gastroenterol Hepatol. 2023 Nov 9:S1542-3565(23)00912.
PubMed Abstract available

WANG Z, Verstockt B, Sabino J, Ferrante M, et al
Therapeutic Drug Monitoring Can Guide the Intravenous-to-Subcutaneous Switch of Infliximab and Vedolizumab: A Simulation Study.
Clin Gastroenterol Hepatol. 2023;21:3188-3190.
PubMed

October 2023

MARILD K, Soderling J, Axelrad J, Halfvarson J, et al
Histological activity in inflammatory bowel disease and risk of serious infections: A nationwide study.
Clin Gastroenterol Hepatol. 2023 Oct 30:S1542-3565(23)00855.
PubMed Abstract available

SHAH RS, Bachour S, Joseph A, Xiao H, et al
Real World Surgical and Endoscopic Recurrence Based on Risk Profiles and Prophylaxis Utilization in Postoperative Crohn's Disease.
Clin Gastroenterol Hepatol. 2023 Oct 23:S1542-3565(23)00851.
PubMed Abstract available

DIGNASS A, Stremmel W, Horynski M, Poyda O, et al
Modified-release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-blind, Randomized, Placebo-controlled Trials.
Clin Gastroenterol Hepatol. 2023 Oct 6:S1542-3565(23)00771.
PubMed Abstract available

JANGI S, Hsia K, Zhao N, Kumamoto CA, et al
Dynamics of the Gut Mycobiome in Patients with Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00762.
PubMed Abstract available

A B, M N, B P, M F, et al
Switching from intra-venous to subcutaneous infliximab is safe and feasible in patients with inflammatory bowel disease suffering from obesity: a post-hoc analysis of the REMSWITCH study.
Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00766.
PubMed

GEEM D, Hercules D, Pelia RS, Venkateswaran S, et al
Progression of Pediatric Crohn's Disease is Associated with Anti-TNF Timing and BMI Z-Score Normalization.
Clin Gastroenterol Hepatol. 2023 Oct 4:S1542-3565(23)00757.
PubMed Abstract available

ULRICH JA, Habash NW, Ismail YA, Tremaine WJ, et al
Effectiveness of Hepatitis B Vaccination for Patients With Inflammatory Bowel and Celiac Disease.
Clin Gastroenterol Hepatol. 2023;21:2901-2907.
PubMed Abstract available

BICKSTON SJ, Kaur H
Higher Rates of Smoking Cessation as a Cause for a Rise in Pouchitis.
Clin Gastroenterol Hepatol. 2023;21:2988-2989.
PubMed

YARUR AJ, McGovern D, Abreu MT, Cheifetz A, et al
Combination Therapy With Immunomodulators Improves the Pharmacokinetics of Infliximab But Not Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol. 2023;21:2908-2917.
PubMed Abstract available

September 2023

WILS P, Jairath V, Sands BE, Reinisch W, et al
Washout periods in inflammatory bowel disease trials: A systematic literature review and proposed solutions.
Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00747.
PubMed

COLOMBEL JF, Ungaro RC, Sands BE, Siegel CA, et al
Vedolizumab, Adalimumab, and Methotrexate Combination Therapy in Crohn's Disease (EXPLORER).
Clin Gastroenterol Hepatol. 2023 Sep 22:S1542-3565(23)00746.
PubMed Abstract available

WILSON A, Chande N, Ponich T, Gregor JC, et al
HLADQA1*05G>A genetic-screening promotes the safe delivery of combination therapy in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2023 Sep 19:S1542-3565(23)00710.
PubMed

ODUFALU FD, Loftus EV Jr, Balzora S
Crohn's Disease: an Equal Opportunity Burden.
Clin Gastroenterol Hepatol. 2023 Sep 12:S1542-3565(23)00702.
PubMed

SOLITANO V, Moschetta A
Metabolic dysfunction-associated steatotic liver disease (MASLD) in inflammatory bowel disease (IBD): a proposed stepwise approach.
Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00669.
PubMed

CAMILLERI M, Zheng DST
Cannabinoids and the GI Tract.
Clin Gastroenterol Hepatol. 2023 Sep 5:S1542-3565(23)00668.
PubMed Abstract available

DALAL RS, Kallumkal G, Cabral HJ, Bachour S, et al
Comparative Effectiveness of Upadacitinib Versus Ustekinumab for Ulcerative Colitis: A Multicenter Retrospective Cohort Study.
Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00671.
PubMed

MCCURDY JD, Stwalley D, Olsen MA, Deepak P, et al
Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn's disease.
Clin Gastroenterol Hepatol. 2023 Sep 4:S1542-3565(23)00664.
PubMed Abstract available

IBING S, Cho JH, Bottinger EP, Ungaro RC, et al
Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
Clin Gastroenterol Hepatol. 2023;21:2629-2638.
PubMed Abstract available

LIMKETKAI BN, Godoy-Brewer G, Parian AM, Noorian S, et al
Dietary Interventions for the Treatment of Inflammatory Bowel Diseases: An Updated Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2023;21:2508-2525.
PubMed Abstract available

HALMA JC, Cristoferi L, Carbone M
The Time is Ripe for a Randomized Controlled Trial of Oral Vancomycin in Primary Sclerosing Cholangitis.
Clin Gastroenterol Hepatol. 2023;21:2699-2700.
PubMed

ATIA O, Benchimol EI, Ledderman N, Greenfeld S, et al
Incidence, Management, and Outcomes of Very Early Onset Inflammatory Bowel Diseases and Infantile-Onset Disease: An Epi-IIRN Study.
Clin Gastroenterol Hepatol. 2023;21:2639-2648.
PubMed Abstract available

WANG M, Auerbach A, Oreper SM, Hohmann SF, et al
Leveraging a New ICD-10 Diagnosis Code to Characterize Hospitalized Patients With Primary Sclerosing Cholangitis.
Clin Gastroenterol Hepatol. 2023;21:2692-2694.
PubMed

MEYER A, Rios P, Drouin J, Weill A, et al
Maternal Exposure to Anti-TNF or Thiopurines for IBD Does Not Increase Risk of Early-life Malignancy in Children.
Clin Gastroenterol Hepatol. 2023;21:2679-2681.
PubMed

XU L, He B, Sun Y, Li J, et al
Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study.
Clin Gastroenterol Hepatol. 2023 Sep 1:S1542-3565(23)00662.
PubMed Abstract available

August 2023

ANG J, Berggreen P, Couto J, Goh L, et al
Principles to advance value in inflammatory bowel disease: a collaborative payer-provider framework.
Clin Gastroenterol Hepatol. 2023 Aug 14:S1542-3565(23)00628.
PubMed

ZHOU A, Srinivasan A, Vasudevan A
Biologic choice should be guided by disease severity not malignancy in patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2023 Aug 3:S1542-3565(23)00581.
PubMed

DAMAS OM, Maldonado-Contreras A
Breaking Barriers in Dietary Research: Strategies to Diversify Recruitment in Clinical Studies and Develop Culturally Tailored Diets for Hispanic Communities Living With Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2023;21:2169-2173.
PubMed

BUISSON A, Nachury M, Reymond M, Yzet C, et al
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
Clin Gastroenterol Hepatol. 2023;21:2338-2346.
PubMed Abstract available

LOFTUS EV JR, Paul S, Roblin X
Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too Early to Conclude.
Clin Gastroenterol Hepatol. 2023;21:2193-2194.
PubMed

July 2023

BRENNER EJ, Zhang X, Long MD, Dubinsky MC, et al
High Use of Estrogen-based Contraceptives in Young Women with Inflammatory Bowel Disease in the United States.
Clin Gastroenterol Hepatol. 2023 Jul 21:S1542-3565(23)00541.
PubMed

WARD D, Andersen NN, Gortz S, Iversen AT, et al
Tumour necrosis factor inhibitors in inflammatory bowel disease and risk of immune mediated inflammatory diseases.
Clin Gastroenterol Hepatol. 2023 Jul 11:S1542-3565(23)00532.
PubMed Abstract available

DEEPAK P, Barnes EL, Shaukat A
Health Disparities in Inflammatory Bowel Disease Care Driven by Rural Versus Urban Residence: Challenges and Potential Solutions.
Clin Gastroenterol Hepatol. 2023;21:1681-1686.
PubMed

BOURGONJE AR, Otten AT
The Risk of Developing Long COVID in Patients With Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter?
Clin Gastroenterol Hepatol. 2023;21:1971-1972.
PubMed

KHAN N, Mahmud N, Patel M, Sundararajan R, et al
Incidence of Long COVID and Impact of Medications on the Risk of Developing Long COVID in a Nationwide Cohort of IBD Patients.
Clin Gastroenterol Hepatol. 2023;21:1960-1962.
PubMed

FLUXA D, Stocchi L, Hashash JG
Rectal Cuff Adenocarcinoma: Rare Complication in Patients with Ileal Pouch-Anal Anastomosis.
Clin Gastroenterol Hepatol. 2023;21:A41-A42.
PubMed

June 2023

WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
Delayed Ustekinumab Responders in Ulcerative Colitis Have Greater Inflammatory Burden but Similar Outcomes as Early Responders.
Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00496.
PubMed Abstract available

COLOMBEL JF, Sands BE, Gasink C, Yeager B, et al
Evolution of symptoms after ustekinumab induction therapy in patients with Crohn's disease.
Clin Gastroenterol Hepatol. 2023 Jun 28:S1542-3565(23)00499.
PubMed Abstract available

KHANNA R, Ma C, Hogan M, Zou G, et al
Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study.
Clin Gastroenterol Hepatol. 2023 Jun 10:S1542-3565(23)00453.
PubMed Abstract available

BEN-HORIN S, Salomon N, Karampekos G, Viazis N, et al
Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trial.
Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00445.
PubMed Abstract available

HABASH N, Abash I
Response to the letter to the editor "Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.".
Clin Gastroenterol Hepatol. 2023 Jun 9:S1542-3565(23)00455.
PubMed

BARNES EL, Long MD, Raffals L, Isaacs K, et al
Development of the Endoscopic Pouch Score for Assessment of Inflammatory Conditions of the Pouch.
Clin Gastroenterol Hepatol. 2023;21:1663-1666.
PubMed Abstract available

FLISS ISAKOV N, Kornblum J, Zemel M, Cohen NA, et al
The Effect of the Crohn's Disease Exclusion Diet on Patients With Pouch Inflammation: An Interventional Pilot Study.
Clin Gastroenterol Hepatol. 2023;21:1654-1656.
PubMed Abstract available

May 2023

HU W, Liao X, Chen Y
Is it a case of ileal Crohn's disease?
Clin Gastroenterol Hepatol. 2023 May 26:S1542-3565(23)00385.
PubMed

KARIME C, Hashash JG, Farraye FA
Measuring of Post-vaccination Hepatitis-B Titers in Patients with Inflammatory Bowel Disease: Thoughts for Further Investigation.
Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00348.
PubMed

YU A, Ha NB, Shi B, Cheng YW, et al
Real-World Experience with Tofacitinib Dose De-escalation in Patients with Moderate and Severe Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00344.
PubMed Abstract available

HUTFLESS S, Jasper RA, Chen PH, Joseph S, et al
Burden of Crohn's Disease in the United States Medicaid Population, 2010 - 2019.
Clin Gastroenterol Hepatol. 2023 May 13:S1542-3565(23)00346.
PubMed Abstract available

NEWMAN KL, Chedid VG, Boden EK
A Systematic Review of Inflammatory Bowel Disease Epidemiology and Health Outcomes in Sexual and Gender Minority Individuals.
Clin Gastroenterol Hepatol. 2023;21:1127-1133.
PubMed

DAI C, Jiang M, Huang YH
Appendectomy and Future Risk of Microscopic Colitis: Correlation or Causation?
Clin Gastroenterol Hepatol. 2023;21:1376-1377.
PubMed

DE SOUSA HT, Gullo I, Magro F
Fibromuscular Expansion in Crohn's Disease Ileal Strictures: An Open Issue.
Clin Gastroenterol Hepatol. 2023;21:1378-1380.
PubMed

KAYAL M, Ungaro RC, Bader G, Colombel JF, et al
Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data.
Clin Gastroenterol Hepatol. 2023;21:1348-1350.
PubMed Abstract available

April 2023

OLEN O, Smedby PKE, Erichsen R, Pedersen PL, et al
Increasing risk of lymphoma over time in Crohn's disease but not in ulcerative colitis: a Scandinavian cohort study.
Clin Gastroenterol Hepatol. 2023 Apr 13:S1542-3565(23)00268.
PubMed Abstract available

BONESCHANSKER L, Ananthakrishnan AN
Comparative effectiveness of upadacitinib and tofacitinib in inducing remission in ulcerative colitis: real world data.
Clin Gastroenterol Hepatol. 2023 Apr 7:S1542-3565(23)00248.
PubMed

SOLITANO V, Facciorusso A, Jess T, Ma C, et al
Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2023;21:907-921.
PubMed Abstract available

MENDALL MA
Obesity and Risk of Crohn's Disease Half the Story.
Clin Gastroenterol Hepatol. 2023;21:1121-1122.
PubMed

March 2023

WETWITTAYAKHLANG P, Golovics PA, Gonczi L, Lakatos L, et al
Stable Incidence and Risk Factors of Colorectal Cancer in Ulcerative Colitis:A Population-based Cohort between 1977-2020.
Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00230.
PubMed

CONSTANTINE-COOKE N, Monterrubio-Gomez K, Plevris N, Derikx LAAP, et al
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn's Disease.
Clin Gastroenterol Hepatol. 2023 Mar 31:S1542-3565(23)00234.
PubMed Abstract available

FITZPATRICK JA, Halmos EP, Machado PP, Gibson PR, et al
Ultra-processed foods and risk of Crohn's disease: how much is too much?
Clin Gastroenterol Hepatol. 2023 Mar 24:S1542-3565(23)00217.
PubMed

COHEN BL, Lincango E, Holubar SD
How to Manage Targeted Immune Suppressants (Biologics and Oral Small-molecule Drugs) Perioperatively for Inflammatory Bowel Disease and non-Inflammatory Bowel Disease surgery.
Clin Gastroenterol Hepatol. 2023 Mar 16:S1542-3565(23)00147.
PubMed

CARON B, Ghosh S, Danese S, Peyrin-Biroulet L, et al
Identifying, understanding and managing fecal urgency in inflammatory bowel diseases.
Clin Gastroenterol Hepatol. 2023 Mar 9:S1542-3565(23)00172.
PubMed Abstract available

FRIEDBERG S, Choi D, Hunold T, Choi NK, et al
Upadacitinib is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience.
Clin Gastroenterol Hepatol. 2023 Mar 8:S1542-3565(23)00173.
PubMed Abstract available

SAEVIK F
Prediction of postoperative recurrence in Crohn's disease: where do we go from here?
Clin Gastroenterol Hepatol. 2023 Mar 3:S1542-3565(23)00170.
PubMed

TABATABAVAKILI S, Targownik LE
Can an Inspiration Around Perspiration Lead to an Innovation In IBD Management?
Clin Gastroenterol Hepatol. 2023;21:617-618.
PubMed

TE GROEN M, Hoentjen F
Confirming Effectiveness of Endoscopic Colon Cancer Screening in Inflammatory Bowel Disease: The Puzzle Remains Unsolved?
Clin Gastroenterol Hepatol. 2023;21:850-851.
PubMed

VAN DEN BERGHE N, Verstockt B, Vermeire S, Thomas D, et al
Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.
Clin Gastroenterol Hepatol. 2023;21:838-840.
PubMed

February 2023

CHOUNG RS, Petralia F, Torres J, Ungaro RC, et al
Preclinical Serological Signatures are Associated with Complicated Crohn's Disease Phenotype at Diagnosis.
Clin Gastroenterol Hepatol. 2023 Feb 12:S1542-3565(23)00100.
PubMed Abstract available

KAYAL M, Kohler D, Colombel JF, Dubinsky MC, et al
Early Biologic Initiation After Chronic Pouch Inflammation Diagnosis Does Not Impact Clinical Outcomes.
Clin Gastroenterol Hepatol. 2023;21:541-542.
PubMed Abstract available

POKRYSZKA J, Reinisch S, Primas C, Novacek G, et al
Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn's Disease: A Retrospective Case Series.
Clin Gastroenterol Hepatol. 2023;21:532-534.
PubMed Abstract available

January 2023

NARULA N, Chang NH, Mohammad D, Wong ECL, et al
Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2023 Jan 30:S1542-3565(23)00071.
PubMed Abstract available

BOUHNIK Y, De Chambrun GP, Lambert J, Nachury M, et al
Adalimumab in biologic-naive patients with Crohn's disease after resolution of an intra-abdominal abscess: a prospective study from the GETAID.
Clin Gastroenterol Hepatol. 2023 Jan 30:S1542-3565(23)00072.
PubMed Abstract available

HOLMER AK, Luo J, Russ KB, Park S, et al
Comparative Safety of Biologic Agents in Patients with Inflammatory Bowel Disease with Active or Recent Malignancy: A Multi-Center Cohort Study.
Clin Gastroenterol Hepatol. 2023 Jan 12:S1542-3565(23)00029.
PubMed Abstract available

KAYAL M, Posner H, Spencer E, Colombel JF, et al
Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data.
Clin Gastroenterol Hepatol. 2023 Jan 11:S1542-3565(23)00035.
PubMed

SANDBORN WJ, Danese S, Leszczyszyn J, Romatowski J, et al
Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.
Clin Gastroenterol Hepatol. 2023 Jan 6:S1542-3565(23)00007.
PubMed Abstract available

MEYER A, Boutron-Ruault MC, Carbonnel F
Comment on "Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study": Author's reply.
Clin Gastroenterol Hepatol. 2023 Jan 4:S1542-3565(23)00005.
PubMed

KHAN N, Patel M, Sundararajan R
Impact of Biologics on SARS-COV-2 Disease Course When Infused Within 2 Weeks of Acquiring the Infection Among IBD Patients.
Clin Gastroenterol Hepatol. 2023;21:232-233.
PubMed Abstract available

DHEYRIAT L, Ward D, Beaugerie L, Jess T, et al
Risk of Recurrent Acute Arterial Events Associated With Thiopurines and Anti-Tumor Necrosis Factor in Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2023;21:164-172.
PubMed Abstract available

KUCHARZIK T, Wilkens R, D'Agostino MA, Maconi G, et al
Early Ultrasound Response and Progressive Transmural Remission After Treatment With Ustekinumab in Crohn's Disease.
Clin Gastroenterol Hepatol. 2023;21:153-163.
PubMed Abstract available

NGUYEN NH, Luo J, Paul P, Kim J, et al
Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study.
Clin Gastroenterol Hepatol. 2023;21:173-181.
PubMed Abstract available

BARNES EL, Allin KH, Iversen AT, Herfarth HH, et al
Increasing Incidence of Pouchitis Between 1996 and 2018: A Population-Based Danish Cohort Study.
Clin Gastroenterol Hepatol. 2023;21:192-199.
PubMed Abstract available

December 2022

VILLUMSEN M, Poulsen G, Andersen NN, Andersson M, et al
Anti-Tumor Necrosis Factor Treatment does not decrease the Risk of Type 2 Diabetes in Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Dec 22:S1542-3565(22)01178.
PubMed

NARULA N, Wong ECL, Pray C, Marshall JK, et al
Associations of Antibiotics, Hormonal Therapies, Oral Contraceptives, and Long-Term NSAIDs with Inflammatory Bowel Disease: Results from the Prospective Urban Rural Epidemiology (PURE) Study.
Clin Gastroenterol Hepatol. 2022 Dec 14:S1542-3565(22)01129.
PubMed Abstract available

FURFARO F, D'Amico F, Zilli A, Craviotto V, et al
Non-invasive assessment of postoperative disease recurrence in Crohn's Disease: a multicenter, prospective cohort study on behalf of the IG-IBD.
Clin Gastroenterol Hepatol. 2022 Dec 12:S1542-3565(22)01131.
PubMed Abstract available

GIRI S
Cross-Sectional Imaging May Serve a Greater Purpose in Postoperative Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:2925.
PubMed

BEELEN EMJ, Nieboer D, Arkenbosch JHC, Regueiro MD, et al
Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials.
Clin Gastroenterol Hepatol. 2022;20:2741-2752.
PubMed Abstract available

MESERVE J, Ma C, Dulai PS, Jairath V, et al
Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2022;20:2728-2740.
PubMed Abstract available

BARNES EL, Kappelman MD, Zhang X, Long MD, et al
Patients With Pouchitis Demonstrate a Significant Cost Burden in the First Two Years After Ileal Pouch-Anal Anastomosis.
Clin Gastroenterol Hepatol. 2022;20:2908-2910.
PubMed Abstract available

LOFTUS EV JR, Colombel JF, Takeuchi K, Gao X, et al
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment.
Clin Gastroenterol Hepatol. 2022 Dec 1:S1542-3565(22)01109.
PubMed Abstract available

November 2022

ANDO Y, Yodoshi T, Yoshioka T
Comment on "Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study".
Clin Gastroenterol Hepatol. 2022 Nov 23:S1542-3565(22)01098.
PubMed

BUISSON A, Nachury M, Fumery M
Checking the absence of inflammatory activity with an objective marker, a key point to succeed the switch from intravenous to subcutaneous infliximab in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2022 Nov 16:S1542-3565(22)01084.
PubMed

ALAYO Q, Deepak P
Reply to Letter to the Editor: Inflammatory Bowel Disease and Incident Acute Arterial Events in the United Kingdom Biobank.
Clin Gastroenterol Hepatol. 2022 Nov 12. pii: S1542-3565(22)01052.
PubMed

PAPAMICHAEL K, Vande Casteele N, Abraham BP, Ritter T, et al
Prior antibodies to infliximab or adalimumab are related to immunogenicity to vedolizumab in patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2022 Nov 10. pii: S1542-3565(22)01053.
PubMed

SINGH S, Kim J, Luo J, Paul P, et al
Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
Clin Gastroenterol Hepatol. 2022 Nov 4:S1542-3565(22)01018.
PubMed Abstract available

MAHMOUD R, Savelkoul EHJ, Jharap B, Oldenburg B, et al
Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse- Authors' response.
Clin Gastroenterol Hepatol. 2022 Nov 3. pii: S1542-3565(22)01017.
PubMed

BALASUBRAMANIAM M, Nandi N, Aswani-Omprakash T, Sebastian S, et al
Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia.
Clin Gastroenterol Hepatol. 2022;20:2421-2426.
PubMed

CARON B, Abreu MT, Siegel CA, Panaccione R, et al
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus.
Clin Gastroenterol Hepatol. 2022;20:2619-2627.
PubMed Abstract available

HANZEL J, Jairath V, Ma C, Guizzetti L, et al
Responsiveness of Magnetic Resonance Enterography Indices for Evaluation of Luminal Disease Activity in Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:2598-2606.
PubMed Abstract available

LEY D, Leroyer A, Dupont C, Sarter H, et al
New Therapeutic Strategies Have Changed the Natural History of Pediatric Crohn's Disease: A Two-Decade Population-Based Study.
Clin Gastroenterol Hepatol. 2022;20:2588-2597.
PubMed Abstract available

GIRI S, Angadi S, Jearth V
Deep Remission in Crohn's Disease: Optional or Quintessential.
Clin Gastroenterol Hepatol. 2022;20:2654-2655.
PubMed

October 2022

THOMAS AS, Hanauer S, Wang Y
Immune Checkpoint inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Oct 18. pii: S1542-3565(22)00961.
PubMed Abstract available

MEYER A, Dong C, Casagrande C, Chan S, et al
Food processing and risk of Crohn's disease and ulcerative colitis: A European Prospective Cohort Study.
Clin Gastroenterol Hepatol. 2022 Oct 12. pii: S1542-3565(22)00929.
PubMed Abstract available

CHANG HC, Gau SY
Inflammatory Bowel Disease and Incident Acute Arterial Events.
Clin Gastroenterol Hepatol. 2022 Oct 8. pii: S1542-3565(22)00927.
PubMed

CHENG D, Kochar BD, Cai T, Ananthakrishnan AN, et al
Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor alpha Antagonists in Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2022;20:2366-2372.
PubMed Abstract available

KOCHAR B, Jylhava J, Soderling J, Ritchie CS, et al
Prevalence and Implications of Frailty in Older Adults With Incident Inflammatory Bowel Diseases: A Nationwide Cohort Study.
Clin Gastroenterol Hepatol. 2022;20:2358-2365.
PubMed Abstract available

D'HAENS G, Panes J, Louis E, Lacerda A, et al
Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study.
Clin Gastroenterol Hepatol. 2022;20:2337-2346.
PubMed Abstract available

BACHOUR SP, Shah RS, Lyu R, Nakamura T, et al
Test Characteristics of Cross-sectional Imaging and Concordance With Endoscopy in Postoperative Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:2327-2336.
PubMed Abstract available

September 2022

OKAFOR PN, Dahlen A, Youssef M, Olayode A, et al
Environmental Pollutants are Associated with Irritable Bowel Syndrome in a Commercially Insured Cohort of California Residents.
Clin Gastroenterol Hepatol. 2022 Sep 30. pii: S1542-3565(22)00923.
PubMed Abstract available

LITTLE RD, Ward MG, Sparrow MP
Letter to the Editor: can subcutaneous infliximab replace dose-intensified intravenous administration in inflammatory bowel disease?
Clin Gastroenterol Hepatol. 2022 Sep 22. pii: S1542-3565(22)00913.
PubMed

DAI C, Jiang M, Huang YH
Anti-TNF withdrawal in inflammatory bowel disease with endoscopic healing and the Risk of Relapse.
Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00914.
PubMed

HASHASH JG, Desai A, Kochhar GS, Farraye FA, et al
Efficacy of Paxlovid and Lagevrio for COVID-19 Infection in patients with Inflammatory Bowel Disease: A Propensity Matched Study.
Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00908.
PubMed

PEYRIN-BIROULET L, Rahier JF, Kirchgesner J, Abitbol V, et al
I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2022 Sep 21. pii: S1542-3565(22)00916.
PubMed Abstract available

ALAYO Q, Loftus EV Jr, Yarur A, Alvarado D, et al
Inflammatory Bowel Disease is associated with an Increased Risk of Incident Acute Arterial Events: Analysis of the United Kingdom Biobank.
Clin Gastroenterol Hepatol. 2022 Sep 5. pii: S1542-3565(22)00831.
PubMed Abstract available

MAGRO F, Magalhaes D, Patita M, Arroja B, et al
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years.
Clin Gastroenterol Hepatol. 2022;20:2059-2073.
PubMed Abstract available

LAHARIE D, D'Haens G, Nachury M, Lambrecht G, et al
Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial.
Clin Gastroenterol Hepatol. 2022;20:2074-2082.
PubMed Abstract available

FUDMAN DI, Perez-Reyes AE, Niccum BA, Melmed GY, et al
Interventions to Decrease Unplanned Healthcare Utilization and Improve Quality of Care in Adults With Inflammatory Bowel Disease: A Systematic Review.
Clin Gastroenterol Hepatol. 2022;20:1947-1970.
PubMed Abstract available

August 2022

MAHMOUD R, Savelkoul EHJ, Mares W, Goetgebuer R, et al
Complete endoscopic healing is associated with a lower relapse risk after anti-TNF withdrawal in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2022 Aug 30. pii: S1542-3565(22)00820.
PubMed Abstract available

WHALEY KG, Xiong Y, Karns R, Hyams JS, et al
MULTICENTER COHORT STUDY OF INFLIXIMAB PHARMACOKINETICS AND THERAPY RESPONSE IN PEDIATRIC ACUTE SEVERE ULCERATIVE COLITIS.
Clin Gastroenterol Hepatol. 2022 Aug 25. pii: S1542-3565(22)00812.
PubMed Abstract available

WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
Predictors of Placebo Induction Response and Remission in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2022 Aug 24. pii: S1542-3565(22)00811.
PubMed Abstract available

STRAATMIJER T, van der Meulen AE, Duijvestein M
Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons? Authors' reply.
Clin Gastroenterol Hepatol. 2022 Aug 9. pii: S1542-3565(22)00739.
PubMed

SAUK JS, Ryu HJ, Labus JS, Khandadash A, et al
High Perceived Stress is Associated with Increased Risk of Ulcerative Colitis Clinical Flares.
Clin Gastroenterol Hepatol. 2022 Aug 8. pii: S1542-3565(22)00721.
PubMed Abstract available

DULAI PS, Feagan BG, Sands BE, Chen J, et al
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2022 Aug 4. pii: S1542-3565(22)00718.
PubMed Abstract available

LONG MD, Weaver KN, Zhang X, Chun K, et al
Strong Response to SARS-CoV-2 Vaccine Additional Doses Among Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2022;20:1881-1883.
PubMed Abstract available

OLLECH JE, Bannon L, Maharshak N, Bar N, et al
Fecal Calprotectin Is Increased in Pouchitis and Progressively Increases With More Severe Endoscopic and Histologic Disease.
Clin Gastroenterol Hepatol. 2022;20:1839-1846.
PubMed Abstract available

KEEFER L, Gorbenko K, Siganporia T, Manning L, et al
Resilience-based Integrated IBD Care Is Associated With Reductions in Health Care Use and Opioids.
Clin Gastroenterol Hepatol. 2022;20:1831-1838.
PubMed Abstract available

MA C
To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:1668-1670.
PubMed

PAUWELS RWM, van der Woude CJ, Nieboer D, Steyerberg EW, et al
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
Clin Gastroenterol Hepatol. 2022;20:1671-1686.
PubMed Abstract available

July 2022

GUBATAN J, Barber GE, Nielsen OH, Juhl CB, et al
Paternal Medications in Inflammatory Bowel Disease and Male Fertility and Reproductive Outcomes: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2022 Jul 20. pii: S1542-3565(22)00675.
PubMed Abstract available

BUIE MJ, Quan BKin J, Windsor JW, Coward S, et al
Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21(st) Century: A Systematic Review with Temporal Analyses.
Clin Gastroenterol Hepatol. 2022 Jul 18. pii: S1542-3565(22)00670.
PubMed Abstract available

ALSOUD D, Verstockt B, Vermeire S
Comparative effectiveness research to position therapies in ulcerative colitis: how fair are the comparisons?
Clin Gastroenterol Hepatol. 2022 Jul 15. pii: S1542-3565(22)00656.
PubMed

JENA A, James D, Singh AK, Dutta U, et al
Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2022;20:1456-1479.
PubMed Abstract available

AKIYAMA S, Rodriguez TG, Rubin DT
Stratifying Risks of Ileal Pouch Outcomes.
Clin Gastroenterol Hepatol. 2022;20:1620-1621.
PubMed

NARULA N, Wong ECL, Dulai PS, Sengupta NK, et al
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:1579-1587.
PubMed Abstract available

BATTAT R, Sandborn WJ
Advances in the Comprehensive Management of Postoperative Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:1436-1449.
PubMed Abstract available

June 2022

RIVIERE P, Bislenghi G, Vermeire S, Domenech E, et al
Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques.
Clin Gastroenterol Hepatol. 2022;20:1201-1204.
PubMed

KOCHAR B, Pate V, Kappelman MD, Long MD, et al
Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
Clin Gastroenterol Hepatol. 2022;20:1299-1305.
PubMed Abstract available

LIU Q, Zhang X, Ko HM, Stocker D, et al
Constrictive and Hypertrophic Strictures in Ileal Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:e1292-e1304.
PubMed Abstract available

DE GREGORIO M, Lee T, Krishnaprasad K, Amos G, et al
Higher Anti-tumor Necrosis Factor-alpha Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
Clin Gastroenterol Hepatol. 2022;20:1306-1314.
PubMed Abstract available

FINK M, Simons M, Tomasino K, Pandit A, et al
When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?
Clin Gastroenterol Hepatol. 2022;20:1241-1250.
PubMed Abstract available

May 2022

STRAATMIJER T, Biemans VB, Visschedijk M, Hoentjen F, et al
Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF experienced ulcerative colitis patients: a nationwide Dutch Registry study.
Clin Gastroenterol Hepatol. 2022 May 26. pii: S1542-3565(22)00510.
PubMed Abstract available

OZEKI K, Tanida S, Kataoka H
Aseptic abscess syndrome with ulcerative colitis and pyoderma gangrenosum.
Clin Gastroenterol Hepatol. 2022 May 25. pii: S1542-3565(22)00512.
PubMed

SCHWARTZ DA, Peyrin-Biroulet L, Lasch K, Adsul S, et al
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
Clin Gastroenterol Hepatol. 2022;20:1059-1067.
PubMed Abstract available

DULAI PS, Wong ECL, Reinisch W, Narula N, et al
Clinical Decision Support Tool for Infliximab in Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:e1192-e1195.
PubMed Abstract available

AHN HJ, Kim YJ, Lee HS, Park JH, et al
High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2022;20:e1022-e1039.
PubMed Abstract available

KAWAMOTO A, Takenaka K, Hibiya S, Ohtsuka K, et al
Serum Leucine-Rich alpha2 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:e1196-e1200.
PubMed Abstract available

SCHAEFER M, Laurent V, Grandmougin A, Vuitton L, et al
A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index.
Clin Gastroenterol Hepatol. 2022;20:e1040-e1049.
PubMed Abstract available

HUANG X, Li X
Infliximab vs Ustekinumab in Biologic Naive Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:e1216.
PubMed

QUINN KP, Urquhart SA, Janssens LP, Lennon RJ, et al
Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype.
Clin Gastroenterol Hepatol. 2022;20:e964-e973.
PubMed Abstract available

April 2022

COHEN NA, Choi D, Choden T, Cleveland NK, et al
Ozanimod in the Treatment of Ulcerative Colitis: Initial Real World Data from A Large Tertiary Center.
Clin Gastroenterol Hepatol. 2022 Apr 2. pii: S1542-3565(22)00310.
PubMed

STEINER CA, Berinstein JA, Louissaint J, Higgins PDR, et al
Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.
Clin Gastroenterol Hepatol. 2022;20:817-846.
PubMed Abstract available

ALLOCCA M, Craviotto V, Bonovas S, Furfaro F, et al
Predictive Value of Bowel Ultrasound in Crohn's Disease: A 12-Month Prospective Study.
Clin Gastroenterol Hepatol. 2022;20:e723-e740.
PubMed Abstract available

CALABRESE E, Rispo A, Zorzi F, De Cristofaro E, et al
Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study.
Clin Gastroenterol Hepatol. 2022;20:e711-e722.
PubMed Abstract available

BLACKWELL J, Saxena S, Jayasooriya N, Petersen I, et al
Stoma Formation in Crohn's Disease and the Likelihood of Antidepressant Use: A Population-Based Cohort Study.
Clin Gastroenterol Hepatol. 2022;20:e703-e710.
PubMed Abstract available

March 2022

SONNENBERG A, Turner KO, Saboorian H, Singhal A, et al
The Occurrence of Gastritis in Microscopic Colitis and Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Mar 23. pii: S1542-3565(22)00294.
PubMed

ANYANE-YEBOA A, Quezada S, Rubin DT, Balzora S, et al
The Impact of the Social Determinants of Health on Disparities in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00285.
PubMed Abstract available

VEYRARD P, Pellet G, Laharie D, Nachury M, et al
Efficacy of induction therapy with calcineurin inhibitors in combination with ustekinumab for acute severe ulcerative colitis.
Clin Gastroenterol Hepatol. 2022 Mar 17. pii: S1542-3565(22)00282.
PubMed

DANESE S, Sands BE, Abreu MT, O'Brien CD, et al
Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-week data from the UNIFI trial.
Clin Gastroenterol Hepatol. 2022 Mar 8. pii: S1542-3565(22)00207.
PubMed Abstract available

BEN-HORIN S, Har-Noy O, Katsanos KH, Roblin X, et al
Corticosteroids and 5-ASA versus corticosteroids for acute severe ulcerative colitis: A randomized controlled trial.
Clin Gastroenterol Hepatol. 2022 Mar 7. pii: S1542-3565(22)00213.
PubMed Abstract available

TARGOWNIK LE, Bernstein CN, Benchimol EI, Kaplan GG, et al
Earlier Anti-TNF Initiation Leads to Long Term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2022 Mar 2. pii: S1542-3565(22)00147.
PubMed Abstract available

PUDIPEDDI A, Paramsothy S, Leong RW
Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?
Clin Gastroenterol Hepatol. 2022;20:e640-e641.
PubMed

ATIA O, Asayag N, Focht G, Lujan R, et al
Perianal Crohn's Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort.
Clin Gastroenterol Hepatol. 2022;20:e484-e495.
PubMed Abstract available

SANDBORN WJ, Rebuck R, Wang Y, Zou B, et al
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial.
Clin Gastroenterol Hepatol. 2022;20:578-590.
PubMed Abstract available

GUILLO L, Rabaud C, Choy EH, D'Amico F, et al
Herpes Zoster and Vaccination Strategies in Inflammatory Bowel Diseases: A Practical Guide.
Clin Gastroenterol Hepatol. 2022;20:481-490.
PubMed Abstract available

February 2022

KIM HS, Hernaez R, Sansgiry S, Waljee AK, et al
Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Feb 28. pii: S1542-3565(22)00205.
PubMed Abstract available

RODRIGUEZ-DUQUE JC, Calleja JL, Iruzubieta P, Hernandez-Conde M, et al
Increased risk of MAFLD and liver fibrosis in inflammatory bowel disease independent of classic metabolic risk factors.
Clin Gastroenterol Hepatol. 2022 Feb 3. pii: S1542-3565(22)00093.
PubMed Abstract available

HUANG X, Li X
Predictive Value of Bowel Ultrasound in Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:e345-e346.
PubMed

HUNTER JO
Dietary Treatment of Crohn's Disease in Adults.
Clin Gastroenterol Hepatol. 2022;20:e343.
PubMed

NG A
Maintenance Therapy in Crohn's Disease: Does the Drug Matter?
Clin Gastroenterol Hepatol. 2022;20:472-473.
PubMed

KAYAL M, Ungaro RC, Colombel JF
The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus.
Clin Gastroenterol Hepatol. 2022;20:281-282.
PubMed

LUCAS UEMURA K, Sousa Freitas Queiroz N, Lees CW
What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?
Clin Gastroenterol Hepatol. 2022;20:468-469.
PubMed

SINGH S, Heien HC, Herrin J, Dulai PS, et al
Comparative Risk of Serious Infections With Tumor Necrosis Factor alpha Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2022;20:e74-e88.
PubMed Abstract available

VANDE CASTEELE N, Abreu MT, Flier S, Papamichael K, et al
Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
Clin Gastroenterol Hepatol. 2022;20:465-467.
PubMed Abstract available

BROCHARD C, Rabilloud ML, Hamonic S, Bajeux E, et al
Natural History of Perianal Crohn's Disease: Long-term Follow-up of a Population-Based Cohort.
Clin Gastroenterol Hepatol. 2022;20:e102-e110.
PubMed Abstract available

KAMBOJ AK, Kane SV, Leggett CL
Crohn's Disease of the Esophagus.
Clin Gastroenterol Hepatol. 2022;20:A15-A16.
PubMed

January 2022

MAHMOUD R, Schultheiss JPD, Louwers JM, van der Kaaij MT, et al
Immunomodulator withdrawal from anti-TNF therapy is not associated with loss of response in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2022 Jan 28. pii: S1542-3565(22)00073.
PubMed Abstract available

LOPES EW, Lochhead P, Burke KE, Richter JM, et al
Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype.
Clin Gastroenterol Hepatol. 2022 Jan 11. pii: S1542-3565(22)00026.
PubMed Abstract available

FREY S, Chowdhury R, Connolly CM, Werbel WA, et al
Antibody Response Six Months after SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2022 Jan 5. pii: S1542-3565(22)00003.
PubMed

KAWADA T
Stoma Formation and Antidepressant Use in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2022;20:245-246.
PubMed

HANZEL J, Ma C, Zou G, Singh S, et al
Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT.
Clin Gastroenterol Hepatol. 2022;20:236-238.
PubMed Abstract available

HASHASH JG, Knisely MR, Germain A, McAuliff K, et al
Brief Behavioral Therapy and Bupropion for Sleep and Fatigue in Young Adults With Crohn's Disease: An Exploratory Open Trial Study.
Clin Gastroenterol Hepatol. 2022;20:96-104.
PubMed Abstract available

ALMUHAIDB A, Sina J, Chen CH
Unusual Presentation of a Crohn's Disease Patient: Not Your Typical Flare.
Clin Gastroenterol Hepatol. 2022;20:e5-e6.
PubMed

December 2021

KAKUTA Y, Shirai T, McGovern DPB, Braun J, et al
Novel diagnostic autoantibodies against Endothelial Protein C Receptor in patients with ulcerative colitis.
Clin Gastroenterol Hepatol. 2021 Dec 28. pii: S1542-3565(21)01359.
PubMed

LEV-TZION R, Focht G, Lujan R, Mendelovici A, et al
COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation.
Clin Gastroenterol Hepatol. 2021 Dec 23. pii: S1542-3565(21)01350.
PubMed Abstract available

CHARILAOU P, Tricarico C, Battat R, Scherl EJ, et al
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS CoV-2 Vaccination.
Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01301.
PubMed

SCHELL TL, Richard LJ, Tippins K, Russ RK, et al
High but Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Dec 8. pii: S1542-3565(21)01308.
PubMed

BAMIAS G, Cominelli F
Exploring the Early Phase of Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:2469-2480.
PubMed Abstract available

SHAFER LA, Sofia MA, Rubin DT, Steinhart AH, et al
An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI.
Clin Gastroenterol Hepatol. 2021;19:2524-2531.
PubMed Abstract available

November 2021

LUKIN DJ, Funez-dePagnier G, Lima S, Lai D, et al
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.
Clin Gastroenterol Hepatol. 2021;19:2312-2314.
PubMed

DEBNATH P, Rathi P
Treat to Target in Patients with Ileocolonic Crohn's Disease: Endoscopic Remission or Histologic Healing?
Clin Gastroenterol Hepatol. 2021;19:2452.
PubMed

COHEN-MEKELBURG S, Yu X, Costa D, Hofer TP, et al
Variation in Provider Connectedness Associates With Outcomes of Inflammatory Bowel Diseases in an Analysis of Data From a National Health System.
Clin Gastroenterol Hepatol. 2021;19:2302-2311.
PubMed Abstract available

October 2021

KUMAR R, Zaghiyan K, Ha C
Lower Surgical Risks in "Contemporary" IBD Cohorts: A Reflection of Better Quality of Care or Statistics?
Clin Gastroenterol Hepatol. 2021;19:2029-2030.
PubMed

DEBNATH P, Rathi P
Outcomes Related to Mucosal Healing in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:2214.
PubMed

FENSTER M, Alayo QA, Khatiwada A, Wang W, et al
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium.
Clin Gastroenterol Hepatol. 2021;19:2207-2209.
PubMed Abstract available

QIAN AS, Nguyen NH, Elia J, Ohno-Machado L, et al
Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:2054-2063.
PubMed Abstract available

SCOTT FI, Hans AK, Gerich ME, Fennimore B, et al
Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:2082-2092.
PubMed Abstract available

SOH H, Lee HJ, Han K, Park S, et al
Atopic Diseases Are Associated With Development of Inflammatory Bowel Diseases in Korea: A Nationwide Population-based Study.
Clin Gastroenterol Hepatol. 2021;19:2072-2081.
PubMed Abstract available

September 2021

GUPTA A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN, et al
Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2021;19:1800-1813.
PubMed Abstract available

PLEVRIS N, Fulforth J, Lyons M, Siakavellas SI, et al
Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:1835-1844.
PubMed Abstract available

HAMDEH S, Micic D, Hanauer S
Drug-Induced Colitis.
Clin Gastroenterol Hepatol. 2021;19:1759-1779.
PubMed Abstract available

August 2021

PUGLIESE D, Privitera G, Schepis T, Larosa L, et al
Drug-related pneumonitis in patients receiving Vedolizumab therapy for Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Aug 31. pii: S1542-3565(21)00921.
PubMed

LO CH, Khandpur N, Rossato SL, Lochhead P, et al
Ultra-processed foods and risk of Crohn's disease and ulcerative colitis: a prospective cohort study.
Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00911.
PubMed Abstract available

BERINSTEIN JA, Cohen-Mekelburg SA, Greenberg GM, Wray D, et al
A Care Coordination Intervention Improves Symptoms but not Charges in High-Risk Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Aug 27. pii: S1542-3565(21)00914.
PubMed Abstract available

WONG ECL, Colombel JF, Riddell R, Marshall JK, et al
Epithelial Neutrophilic Infiltrate - The Rising Star in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00904.
PubMed

SASSON AN, Sheehan G, Yu A, Gupta A, et al
Yield and Predictors of surveillance colonoscopies in older adults with long-standing ulcerative colitis.
Clin Gastroenterol Hepatol. 2021 Aug 20. pii: S1542-3565(21)00899.
PubMed Abstract available

D'SILVA A, Fox DE, Raman M
This Letter to the Editor is in response to: Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease/Dr. Maitreyi Raman.
Clin Gastroenterol Hepatol. 2021 Aug 16. pii: S1542-3565(21)00874.
PubMed

YELENCICH E, Truong E, Widaman AM, Pignotti G, et al
Avoidant Restrictive Food Intake Disorder Prevalent among Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Aug 10. pii: S1542-3565(21)00864.
PubMed Abstract available

ESTEVINHO MM, Magro F
Epithelial neutrophilic infiltrate - the rising star in ulcerative colitis.
Clin Gastroenterol Hepatol. 2021 Aug 5. pii: S1542-3565(21)00835.
PubMed

DALAL RS, McClure E, Marcus J, Winter RW, et al
COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:1730-1732.
PubMed Abstract available

YANAI H, Goren I, Godny L, Maharshak N, et al
Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable.
Clin Gastroenterol Hepatol. 2021;19:1564-1572.
PubMed Abstract available

DE BRUYN JR, Bossuyt P, Ferrante M, West RL, et al
High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn's Disease in a Randomized Placebo-Controlled Trial.
Clin Gastroenterol Hepatol. 2021;19:1573-1582.
PubMed Abstract available

July 2021

RUDRA S, Shaul E, Conrad M, Patel T, et al
Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset- Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00822.
PubMed

NARULA N, Wong ECL, Marshall JK, Colombel JF, et al
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021 Jul 27. pii: S1542-3565(21)00820.
PubMed Abstract available

DAI C, Jiang M, Huang YH
Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Jul 21. pii: S1542-3565(21)00759.
PubMed

MEYER A, Taine M, Drouin J, Weill A, et al
Serious infections in children born to mothers with inflammatory bowel disease with in utero exposure to thiopurines and anti-TNF.
Clin Gastroenterol Hepatol. 2021 Jul 20. pii: S1542-3565(21)00760.
PubMed Abstract available

KHAN N, Wang L, Trivedi C, Pernes T, et al
Efficacy of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Jul 15. pii: S1542-3565(21)00754.
PubMed Abstract available

CHAN SSM, Chen Y, Casey K, Olen O, et al
Obesity is associated with increased risk of Crohn's disease, but not ulcerative colitis: A pooled analysis of five prospective cohort studies.
Clin Gastroenterol Hepatol. 2021 Jul 6. pii: S1542-3565(21)00720.
PubMed Abstract available

NARULA N, Wong ECL, Colombel JF, Riddell R, et al
Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021 Jul 3. pii: S1542-3565(21)00716.
PubMed Abstract available

RODRIGUEZ-LAGO I, Barreiro-de Acosta M
Look at Both Sides of the Coin in Determining Risk of Complicated Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:1503-1504.
PubMed

SEDANO R, Guizzetti L, McDonald C, Jairath V, et al
Intravenous Ustekinumab Reinduction Is Effective in Prior Biologic Failure Crohn's Disease Patients Already on Every-4-Week Dosing.
Clin Gastroenterol Hepatol. 2021;19:1497-1498.
PubMed Abstract available

KAYAL M, Lambin T, Plietz M, Rizvi A, et al
Recycling of Precolectomy Anti-Tumor Necrosis Factor Agents in Chronic Pouch Inflammation Is Associated With Treatment Failure.
Clin Gastroenterol Hepatol. 2021;19:1491-1493.
PubMed Abstract available

HU A, Kotze PG, Burgevin A, Tan W, et al
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
Clin Gastroenterol Hepatol. 2021;19:1366-1376.
PubMed Abstract available

NGUYEN NH, Khera R, Ohno-Machado L, Sandborn WJ, et al
Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:1377-1386.
PubMed Abstract available

MILLIEN V, Abrams D, Khalaf N
Not All Terminal Ileitis Is Crohn's Disease: Intestinal Tuberculosis Causing Small Bowel Obstruction.
Clin Gastroenterol Hepatol. 2021;19:e71.
PubMed

June 2021

D'SILVA A, Fox DE, Nasser Y, Vallance JK, et al
Prevalence and Risk Factors for Fatigue in Adults with Inflammatory Bowel Disease: A Systematic Review with Meta-analysis.
Clin Gastroenterol Hepatol. 2021 Jun 30. pii: S1542-3565(21)00698.
PubMed Abstract available

ASSCHER VER, Waars SN, van der Meulen-de Jong AE, Stuyt RJL, et al
Deficits in geriatric assessment associate with disease activity and -burden in older patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2021 Jun 18. pii: S1542-3565(21)00643.
PubMed Abstract available

CASSINOTTI A, Corona A, Duca P, Nebuloni M, et al
NON INVASIVE MONITORING AFTER AZATHIOPRINE WITHDRAWAL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN DEEP REMISSION.
Clin Gastroenterol Hepatol. 2021 Jun 14. pii: S1542-3565(21)00642.
PubMed Abstract available

DANESE S, Klopocka M, Scherl EJ, Romatowski J, et al
Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study [102/120 characters including spaces].
Clin Gastroenterol Hepatol. 2021 Jun 11. pii: S1542-3565(21)00614.
PubMed Abstract available

AGRAWAL M, Brenner EJ, Yan Mak JW, Zhang X, et al
COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel disease in the United States.
Clin Gastroenterol Hepatol. 2021 Jun 2. pii: S1542-3565(21)00599.
PubMed

FAHAD H, Dulai PS, Shen B, Kochhar GS, et al
Hyperbaric Oxygen Therapy Is Effective in the Treatment of Inflammatory and Fistulizing Pouch Complications.
Clin Gastroenterol Hepatol. 2021;19:1288-1291.
PubMed Abstract available

BRAGA NETO MB, Ramos GP, Loftus EV Jr, Faubion WA, et al
Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
Clin Gastroenterol Hepatol. 2021;19:1285-1287.
PubMed Abstract available

POUILLON L, Remen T, Amicone C, Louis E, et al
Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.
Clin Gastroenterol Hepatol. 2021;19:1218-1225.
PubMed Abstract available

VANDE CASTEELE N, Jairath V, Jeyarajah J, Dulai PS, et al
Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab.
Clin Gastroenterol Hepatol. 2021;19:1209-1217.
PubMed Abstract available

HU AB, Tan W, Deshpande V, Ananthakrishnan AN, et al
Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission.
Clin Gastroenterol Hepatol. 2021;19:1226-1233.
PubMed Abstract available

LAGRANGE J, Lacolley P, Wahl D, Peyrin-Biroulet L, et al
Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:1088-1097.
PubMed Abstract available

May 2021

TROELSEN FS, Sorensen HT, Crockett SD, Pedersen L, et al
Characteristics and survival of patients with inflammatory bowel disease and post-colonoscopy colorectal cancers.
Clin Gastroenterol Hepatol. 2021 May 26. pii: S1542-3565(21)00577.
PubMed Abstract available

BERINSTEIN JA, Sheehan J, Dias M, Berinstein EM, et al
Tofacitinib for Biologic-Experienced Hospitalized Patients with Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Clin Gastroenterol Hepatol. 2021 May 25. pii: S1542-3565(21)00576.
PubMed Abstract available

KAYAL M, Ungaro RC, Riggs A, Kamal K, et al
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis is Associated with Significant Disability.
Clin Gastroenterol Hepatol. 2021 May 22. pii: S1542-3565(21)00571.
PubMed Abstract available

AHMED W, Scott FI
Closing the gap: the real-world risk of serious infections with vedolizumab in comparison to anti-TNF therapy in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2021 May 19. pii: S1542-3565(21)00564.
PubMed

CONSTANT BD, Dutmer CM, Arnold MA, Hall C, et al
Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult to Treat Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 May 6. pii: S1542-3565(21)00504.
PubMed

CON D, Van Langenberg DR, Vasudevan A
Response to: Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlate With Rate of Infection.
Clin Gastroenterol Hepatol. 2021;19:1077.
PubMed

SAGAMI S, Kobayashi T, Miyatani Y, Okabayashi S, et al
Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2021;19:908-921.
PubMed Abstract available

BOSSUYT P, Dreesen E, Rimola J, Devuysere S, et al
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:947-954.
PubMed Abstract available

SINGER AAM, Bloom DA, Adler J
Factors Associated With Development of Perianal Fistulas in Pediatric Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:1071-1073.
PubMed Abstract available

April 2021

CON D, Vasudevan A, van Langenberg DR
Predictive Scores in Acute Severe Ulcerative Colitis: Which, What and When are the Decision Points We Should Target?
Clin Gastroenterol Hepatol. 2021 Apr 24. pii: S1542-3565(21)00469.
PubMed

VOLGER S, Scherl E
Biologics for Inflammatory Bowel Disease and their Safety in Pregnancy.
Clin Gastroenterol Hepatol. 2021 Apr 14. pii: S1542-3565(21)00449.
PubMed

ROTH K, Berinstein JA
Reply: A Patient Perspective on Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease.
Clin Gastroenterol Hepatol. 2021 Apr 8. pii: S1542-3565(21)00446.
PubMed

BHATTACHARYA S, Marciano BE, Malech HL, Quezado M, et al
Safety and efficacy of ustekinumab in the inflammatory bowel disease of chronic granulomatous disease.
Clin Gastroenterol Hepatol. 2021 Apr 1. pii: S1542-3565(21)00349.
PubMed

SORRENTINO D, Geraci M, Kuballa A
Diagnosis of Preclinical Crohn's Disease: Hurdles, Challenges, and Hopes.
Clin Gastroenterol Hepatol. 2021;19:857-858.
PubMed

YZET C, Diouf M, Singh S, Brazier F, et al
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
Clin Gastroenterol Hepatol. 2021;19:668-679.
PubMed Abstract available

SIGALL BONEH R, Van Limbergen J, Wine E, Assa A, et al
Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:752-759.
PubMed Abstract available

RIVIERE P, Vermeire S, Irles-Depe M, Van Assche G, et al
Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic Therapies.
Clin Gastroenterol Hepatol. 2021;19:713-720.
PubMed Abstract available

JESSEN B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, et al
Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab.
Clin Gastroenterol Hepatol. 2021;19:721-731.
PubMed Abstract available

BARNES EL, Kochar B, Herfarth HH, Winter RW, et al
Creation of a Case-Finding Definition for Identifying Patients With Acute Pouchitis in Administrative Claims Data.
Clin Gastroenterol Hepatol. 2021;19:842-844.
PubMed Abstract available

March 2021

AHMED W, Galati J, Kumar A, Christos PJ, et al
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Clin Gastroenterol Hepatol. 2021 Mar 30. pii: S1542-3565(21)00344.
PubMed Abstract available

LOPES EW, Lebwohl B, Burke KE, Ivey KL, et al
DIETARY GLUTEN INTAKE IS NOT ASSOCIATED WITH RISK OF INFLAMMATORY BOWEL DISEASE IN U.S. ADULTS WITHOUT CELIAC DISEASE.
Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00339.
PubMed Abstract available

DALAL RS, Esckilsen S, Barnes EL, Pruce JC, et al
Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study.
Clin Gastroenterol Hepatol. 2021 Mar 25. pii: S1542-3565(21)00338.
PubMed

NAMBU R, Warner N, Mulder DJ, Kotlarz D, et al
A Systematic Review of Monogenic Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Mar 18. pii: S1542-3565(21)00331.
PubMed Abstract available

OKAMOTO T, Fukuda K
Long-term outcomes in asymptomatic ulcerative colitis diagnosed during screening colonoscopy.
Clin Gastroenterol Hepatol. 2021 Mar 11. pii: S1542-3565(21)00275.
PubMed

SANDBORN WJ, Peyrin-Biroulet L, Sharara AI, Su C, et al
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Clin Gastroenterol Hepatol. 2021 Mar 5. pii: S1542-3565(21)00222.
PubMed Abstract available

ALAMEEL T, Al Sulais E
Risk of HBV Reactivation Among IBD patients With Occult Hepatitis B Virus Infection.
Clin Gastroenterol Hepatol. 2021;19:621-622.
PubMed

ANANTHAKRISHNAN AN, Deshpande V
It Is All in the Fine Print: A Call for a Histopathology Checklist for IBD.
Clin Gastroenterol Hepatol. 2021;19:446-447.
PubMed

TANDON P, Malhi G, Abdali D, Pogue E, et al
Active Margins, Plexitis, and Granulomas Increase Postoperative Crohn's Recurrence: Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2021;19:451-462.
PubMed Abstract available

BORREN NZ, Plichta D, Joshi AD, Bonilla G, et al
Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:519-527.
PubMed Abstract available

SASSON AN, Ananthakrishnan AN, Raman M
Diet in Treatment of Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:425-435.
PubMed Abstract available

February 2021

AKHTAR HJ, Nguyen TM, Ma C, Jairath V, et al
Vedolizumab for the treatment of Non-Inflammatory Bowel Disease Related Enteropathy.
Clin Gastroenterol Hepatol. 2021 Feb 19. pii: S1542-3565(21)00204.
PubMed

JANGI S, Holmer AK, Dulai PS, Boland B, et al
Spatial Evolution of Histologic and Endoscopic Healing in Left and Right Colon in Patients with Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021 Feb 5. pii: S1542-3565(21)00108.
PubMed Abstract available

AKIYAMA S, Ollech JE, Rai V, Glick LR, et al
Endoscopic phenotype of the J pouch in patients with inflammatory bowel disease: A new classification for pouch outcomes.
Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00111.
PubMed Abstract available

LONG MD, Siegel CA, Abraham BP, Chiorean M, et al
Day Care Attendance and Infectious Complications in Children Born to Mothers with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2021 Feb 4. pii: S1542-3565(21)00104.
PubMed

FALECK DM, Shmidt E, Huang R, Katta LG, et al
Effect of Concomitant Therapy With Steroids and Tumor Necrosis Factor Antagonists for Induction of Remission in Patients With Crohn's Disease: A Systematic Review and Pooled Meta-analysis.
Clin Gastroenterol Hepatol. 2021;19:238-245.
PubMed Abstract available

BOLAND K, Bedrani L, Turpin W, Kabakchiev B, et al
Persistent Diarrhea in Patients With Crohn's Disease After Mucosal Healing Is Associated With Lower Diversity of the Intestinal Microbiome and Increased Dysbiosis.
Clin Gastroenterol Hepatol. 2021;19:296-304.
PubMed Abstract available

LANDEMAINE A, Petitcollin A, Brochard C, Miard C, et al
Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection.
Clin Gastroenterol Hepatol. 2021;19:288-295.
PubMed Abstract available

January 2021

LAURAIN PA, Guillo L, D'Amico F, Netter P, et al
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study.
Clin Gastroenterol Hepatol. 2021 Jan 22. pii: S1542-3565(21)00078.
PubMed Abstract available

VAN DER SLOOT KWJ, Tiems JL, Visschedijk MC, Festen EAM, et al
Cigarette smoke increases risk for colorectal neoplasia in inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2021 Jan 13. pii: S1542-3565(21)00018.
PubMed Abstract available

DAI C, Huang YH, Jiang M
Two Types of Fecal Tests in Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2021;19:209.
PubMed

DEL HOYO J, Aguas M
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
Clin Gastroenterol Hepatol. 2021;19:206-207.
PubMed

BRENNER EJ, Kappelman MD
Working Together to Meet the Needs of Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:210-211.
PubMed

NAGANUMA M, Kanai T
Reply.
Clin Gastroenterol Hepatol. 2021;19:209-210.
PubMed

LO CH, Khalili H, Song M, Lochhead P, et al
Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol. 2021;19:87-95.
PubMed Abstract available

OLLECH JE, Normatov I, Peleg N, Wang J, et al
Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
Clin Gastroenterol Hepatol. 2021;19:104-110.
PubMed Abstract available

HANZEL J, Zdovc J, Kurent T, Sever N, et al
Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission.
Clin Gastroenterol Hepatol. 2021;19:111-118.
PubMed Abstract available

December 2020

KIRCHGESNER J, Desai RJ, Beaugerie L, Schneeweiss S, et al
Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2020 Dec 30. pii: S1542-3565(20)31726.
PubMed Abstract available

GUILLO L, Uzzan M, Beaugerie L, Gornet JM, et al
Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.
Clin Gastroenterol Hepatol. 2020 Dec 24. pii: S1542-3565(20)31719.
PubMed Abstract available

KHANNA R, Ma C, Jairath V, Casteele NV, et al
Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.
Clin Gastroenterol Hepatol. 2020 Dec 15. pii: S1542-3565(20)31674.
PubMed Abstract available

MA C, Jeyarajah J, Guizzetti L, Parker CE, et al
Modeling Endoscopic Improvement after Induction Treatment with Mesalamine in Patients with Mild-to-Moderate Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Dec 3. pii: S1542-3565(20)31630.
PubMed Abstract available

November 2020

WANG CY, Chen WL, Cheng-Chung Wei J
Link Between Inflammatory Bowel Disease and Risk of Chronic Kidney Disease.
Clin Gastroenterol Hepatol. 2020 Nov 21. pii: S1542-3565(20)31498.
PubMed

VAJRAVELU RK, Copelovitch L, Denburg MR
Letter title: "Link between inflammatory bowel disease and risk of chronic kidney disease" by Wang and colleagues.
Clin Gastroenterol Hepatol. 2020 Nov 20. pii: S1542-3565(20)31565.
PubMed

BRAAT H, Parikh K, Peppelenbosch MP
Complete Resolution of Mucosal Neutrophils May Predict Non-fatigue in Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Nov 19. pii: S1542-3565(20)31559.
PubMed

GRACIE DJ, Ford AC
Bugs and the Brain in Inflammatory Bowel Disease: A Novel Treatment Target?
Clin Gastroenterol Hepatol. 2020 Nov 6. pii: S1542-3565(20)31434.
PubMed

D'AMICO F, Danese S, Peyrin-Biroulet L
Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock.
Clin Gastroenterol Hepatol. 2020;18:2689-2700.
PubMed Abstract available

October 2020

SANDBORN WJ, Peyrin-Biroulet L, Quirk D, Wang W, et al
Efficacy and Safety of Extended Induction with Tofacitinib for the Treatment of Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31496.
PubMed Abstract available

TSAI L, Ma C, Dulai PS, Prokop LJ, et al
Contemporary Risk of Surgery in Patients with Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-based Cohorts.
Clin Gastroenterol Hepatol. 2020 Oct 27. pii: S1542-3565(20)31497.
PubMed Abstract available

OLLECH JE, Avni-Biron I, Glick L, Haider H, et al
Effective Treatment of Acute Severe Ulcerative Colitis in Pregnancy Is Associated with Good Maternal and Fetal Outcomes.
Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31493.
PubMed Abstract available

LI YM, Stettler I, Oungpasuk K
Association Between Provider Connectedness and Inflammatory Bowel Disease Outcomes.
Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31291.
PubMed

STEENHOLDT C, Jensen JT, Brynskov J, Moller AM, et al
Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2020 Oct 22. pii: S1542-3565(20)31495.
PubMed Abstract available

VEDAMURTHY A, Gangasani N, Ananthakrishnan AN
Vedolizumab or TNF-antagonist use and risk of new or recurrent cancer in patients with inflammatory bowel disease with prior malignancy: A retrospective cohort study.
Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31396.
PubMed Abstract available

KHOUDARI G, Mansoor E, Click B, Alkhayyat M, et al
Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients after Initiation of Biologics: A Cohort Study.
Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31397.
PubMed Abstract available

NAESSENS D, Cameron C, Hoaglin DC
Network Meta-Analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects from Induction and Bias of the Results.
Clin Gastroenterol Hepatol. 2020 Oct 13. pii: S1542-3565(20)31428.
PubMed

BRENNER EJ, Pigneur B, Focht G, Zhang X, et al
BENIGN EVOLUTION OF SARS-CoV2 INFECTIONS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM TWO INTERNATIONAL DATABASES.
Clin Gastroenterol Hepatol. 2020 Oct 12. pii: S1542-3565(20)31399.
PubMed

COLOMBEL JF, Osterman MT, Thorpe AJ, Salese L, et al
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31389.
PubMed Abstract available

LUKIN D, Faleck D, Xu R, Zhang Y, et al
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Oct 8. pii: S1542-3565(20)31388.
PubMed Abstract available

September 2020

KIM HJ, Shah SC, Hann HJ, Kazmi SZ, et al
Familial Risk of Inflammatory Bowel Disease - A Population-based Cohort study in South Korea.
Clin Gastroenterol Hepatol. 2020 Sep 30. pii: S1542-3565(20)31384.
PubMed Abstract available

DIMKE H, Winther-Jensen M, Allin KH, Lund L, et al
Risk of Urolithiasis in Patients with Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2020 Sep 29. pii: S1542-3565(20)31379.
PubMed Abstract available

August 2020

STORAN D, Doherty GA, Cullen G
Ustekinumab 90 mg Every 2 Weeks for the Treatment of Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2020 Aug 30. pii: S1542-3565(20)31079.
PubMed

GILMORE R, Hilley P, Srinivasan A, Choy MC, et al
Tofacitinib is Safe and Effective When Used in Combination With Infliximab for the Management of Refractory Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Aug 16. pii: S1542-3565(20)31008.
PubMed

BERINSTEIN JA, Steiner CA, Higgins PDR
Reply to Tofacitinib is safe and effective when used in combination with Infliximab for the management of Refractory Ulcerative Colitis.
Clin Gastroenterol Hepatol. 2020 Aug 12. pii: S1542-3565(20)31132.
PubMed

July 2020

AREBI N, Dyall L, Kamperidis N
A User's Guide to De-Escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2020 Jul 27. pii: S1542-3565(20)30920.
PubMed

June 2020

SCAIOLI E, Salice M, Belluzzi A
Omega-3 as a Part of the Dietary Guidance for Patients with Ulcerative Colitis: Beyond the Natural Sources.
Clin Gastroenterol Hepatol. 2020 Jun 25. pii: S1542-3565(20)30760.
PubMed

PAPAMICHAEL K, Cheifetz AS
Therapeutic Drug Monitoring and Safety of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2020 Jun 5. pii: S1542-3565(20)30638.
PubMed

April 2020

ONA S, Long M, Mitchell C
Reply.
Clin Gastroenterol Hepatol. 2020;18:1002.
PubMed

February 2020

PANSART C, Roblin X, Paul S
Preanalytical Heterogeneity in Fecal Calprotectin Measurement Needs To Be Considered for Tight Control.
Clin Gastroenterol Hepatol. 2020;18:524-525.
PubMed

KENNEDY NA, Lees CW
Reply.
Clin Gastroenterol Hepatol. 2020;18:526.
PubMed

COZIJNSEN MA, Turner D
Reply.
Clin Gastroenterol Hepatol. 2020;18:525-526.
PubMed

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.